Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-EGFRvIII and Keytruda in newly diagnosed glioblastoma
NCT03726515Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EGFRvIII-CAR T cells in glioblastoma (GBM), sponsored by University of Pennsylvania. Primary endpoint: Adverse Events at 15 years. Started Mar 2019; status: completed.
02
Drugs
EGFRvIII-CAR T cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03726515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726515.